Day 28 Shutdown Update:

The federal shutdown reached Day 28 today, entering its fifth week with no funding resolution in sight. What began as a temporary budget impasse is now a slow-motion systems collapse across agencies responsible for food safety, public health, and regulatory oversight.

While FDA and USDA have managed to preserve a skeleton of essential functions, the latest updates underscore how deeply the freeze is cutting: from halted user-fee submissions to suspended federal food-aid benefits scheduled for November 1.

USDA: Federal Food Aid to Halt November 1

In one of the most consequential developments of the shutdown, the U.S. Department of Agriculture confirmed that federal food-aid programs, including the Supplemental Nutrition Assistance Program (SNAP), will not issue November benefits absent new appropriations.
(NBC Chicago, Oct 28 2025)

The agency’s remaining contingency funds have been exhausted, and unlike earlier shutdowns, no short-term reallocations appear feasible. The lapse affects over 40 million Americans, along with associated supply chains—from grocers and distributors to agricultural processors—many of which depend on consistent federal disbursements.

From a regulatory and commercial perspective, this marks a turning point: economic instability now intersects with compliance instability, as funding for inspection, enforcement, and data programs remains unavailable.

FDA: No New Submissions, Dwindling Reviews

The FDA continues to lack legal authority to accept new submissions requiring user-fee payments under the Prescription Drug, Medical Device, Generic Drug, and related fee acts.
(FDA.gov, Oct 2025)

Active Review Work Shrinking

Carryover user-fee balances are keeping a portion of review staff funded, but industry sources confirm that review volume and communication pace are now declining as contractor support and internal cross-office coordination erode.
(SOCMA, Oct 2025)

Submission statistics across key FDA programs show:

• Zero new user-fee filings since October 1.
• Rising backlog of queued submissions, especially in generic drug and 510(k) programs.
• Paused meetings and consultations, including pre-IND and Type C meetings.

Once funding resumes, the FDA will confront a “stacked” queue of filings, many of which will require renewed user-fee payment validation or resubmission to trigger statutory review timelines.

Regulatory Systems: Frozen but Still Online

Agency websites remain visible but static. No updates have been posted to:

• DailyMed (drug labeling database)
• Federal Register FDA/USDA notices
• Guidance or policy documents since September

Similarly, FOIA offices, inspection portals, and enforcement tracking dashboards remain inactive. For regulated entities, the challenge has shifted from visibility to reliability: which online resources still reflect current compliance status, and which no longer do?

Broader Impacts

1. Inspection and Import Delays – Dual-jurisdiction imports (FDA/APHIS) are facing 3–7 day delays in clearance.
2. Registration Renewal Risks – Food, drug, device, and cosmetic facility renewals remain unvalidated; automated systems accept submissions but do not process them.
3. Economic Chain Reactions – The halt of SNAP payments adds pressure on food manufacturers and distributors, potentially triggering demand-side disruptions alongside regulatory uncertainty.

Client Guidance: Sustaining Compliance Amid Institutional Fatigue

With the shutdown now approaching a full month, regulated entities should treat this period not as a temporary lapse but as a distinct regulatory environment.

Recommended actions:

• Maintain proof of all submission attempts, user-fee payments, and renewal filings.
• Identify which compliance tasks depend on federal confirmation and which can proceed autonomously.
• Notify distributors, importers, and co-manufacturers of potential delays in registration verification or import clearance.
• Prepare documentation to justify reliance on pre-shutdown data or guidance, should agencies later question decisions made during this period.

Outlook

Day 28 reflects the new reality: essential operations are running on fumes, while the rest of the regulatory ecosystem is frozen in place. The longer this continues, the more permanent the distortions become—especially for programs dependent on continuous review, inspection, and funding cycles.

When the shutdown ends, agencies will not resume where they left off—they will restart from behind.

FDA Atty will continue monitoring for any restoration of agency services, appropriations action in Congress, and post-lapse recovery guidance.